Study S001665

A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04143802
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 72
Start: 2019-12-18
Primary completion: 2020-12-28
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:LY3437943; DRUG:Dulaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:J1I-MC-GZBB

Registered primary outcomes

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Day 106]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0019180	The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Urva S, Diabetes, obesity & metabolism	2023	Randomized trial	PMID 37311727 DOI	cites ClinicalTrials.gov:NCT04143802
R0014993	LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Urva S, Lancet (London, England)	2022	Randomized trial	PMID 36354040 DOI	cites ClinicalTrials.gov:NCT04143802; registry reference DERIVED:36354040